Silence Therapeutics to Participate in Conferences
Source: RNSSilence Therapeutics to Participate in US Virtual Investor Conferences in August
21 July 2020
LONDON, Silence Therapeutics plc (LON: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that Company management will be participating in three virtual conferences, details of which can be found below:
William Blair Biotech Focus Conference
|
|
|
|
|
Date: |
|
Thursday, August 6, 2020 |
|
Time: |
|
2:00 pm EDT (19:00 BST) |
|
Panel: |
|
30 Years of RNA-Targeted Therapies - Where Are We Now |
BTIG Virtual Biotechnology Conference
|
|
|
|
|
Date: |
|
Monday, August 10, 2020 |
|
Time: |
|
9:30 am EDT (14:30 BST) |
|
Webcast link: |
|
Canaccord 40th Annual Growth Conference
|
|
|
|
|
Date: |
|
Thursday, August 13, 2020 |
|
Time: |
|
11:30 am EDT (16:30 BST) |
|
Webcast link: |
|
Live webcasts of the BTIG Virtual Biotechnology Conference and the Canaccord Growth Conference can be accessed via the Investors section of the Company's website at www.silence-therapeutics.com. An archived replay of the webcasts will be available for 60 days on the Company's website after the conference.
For more information, please contact:
|
Silence Therapeutics plc Iain Ross, Executive Chairman Rob Quinn, Chief Financial Officer
|
Tel: +44 (0)20 3457 6900 |
|
Investec (Nominated Adviser and Broker) Daniel Adams/Gary Clarence
|
Tel: +44 (0) 20 7597 5970 |
|
European IR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray silencetherapeutics@consilium-comms.com
|
Tel: +44 (0) 20 3709 5700 |
|
U.S. IR Westwicke Peter Vozzo peter.vozzo@westwicke.com |
Tel: +1 (443) 213-0505 |
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
